Person: SİVRİOĞLU, ENVER YUSUF
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SİVRİOĞLU
First Name
ENVER YUSUF
Name
3 results
Search Results
Now showing 1 - 3 of 3
Publication Correlation of behavioral and psychological symptoms of alzheimer's disease with caregiver burden, depression and anxiety levels(Cambridge Univ Press, 2003-01-01) Sivrioğlu, Y.; Taneli, B.; Sarandöl, A.; SİVRİOĞLU, ENVER YUSUF; Taneli, Baha; SARANDÖL, ASLI; Uludağ Üniversitesi/Tıp Fakültesi.; DTC-7187-2022; DZC-3645-2022; JKB-3005-2023Publication Can bath ankylosing spondylitis disease activity index be affected by accompanying fibromyalgia or depression?(Turkish League Against Rheumatism, 2015-01-01) Altan, Lale; Sivrioğlu, Yusuf; Ercan, İlker; ALTAN İNCEOĞLU, LALE; SİVRİOĞLU, ENVER YUSUF; ERCAN, İLKER; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0002-2382-290X; AAH-1652-2021; DTC-7187-2022; ABF-2367-2020Objectives: This study aims to investigate whether Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is affected from pathologies such as fibromyalgia (FM) and depression which may coexist in patients with ankylosing spondylitis (AS).Patients and methods: A total of 170 patients (57 males, 123 females; mean age 42.9 +/- 13.0 years) aged between 18 and 75 years with FM (n=52), depression (n=60) and AS (n=58) were included in the study. All patients were asked to complete BASDAI and Beck Depression Inventory. Percentages of patients with BASDAI scores of >4 (cut-off value for disease activity) and >5 (cut-off value for reimbursement of biological agents) were calculated and compared between the groups. Individual BASDAI item scores, total BASDAI, and Beck Depression Inventory scores were compared between the groups.Results: When individual BASDAI items scores were analyzed separately, scores of all items were statistically significantly higher in FM group compared to AS group. While question 1 (fatigue) and 3 (peripheral joint pain and swelling) scores were statistically significantly higher in the depression group compared to AS group, question 5 and 6 scores (items associated with morning stiffness) were significantly lower in the depression group compared to AS group. Percentage of patients with BASDAI scores of >4 and >5 in the FM group was significantly higher compared to the other two groups. Significant correlation was noted between BASDAI and Beck Depression Inventory scores in AS and FM groups.Conclusion: Our findings suggest that while assessing disease activity in patients with AS particularly by a patient-reported outcome measure such as BASDAI, other conditions such as FM and depression which may affect the scores should be taken into consideration.Publication Comparison of effects of sertraline and reboxetine on the loss of social functioning in major depressive disorder: A randomized, open-labeled study(Kare Yayınevi, 2006-01-01) Akkaya, Cengiz; Sivrioğlu, E. Yusuf; Sarandöl, Aslı; Eker, S. Saygın; Kırlı, Selçuk; AKKAYA, CENGİZ; SİVRİOĞLU, ENVER YUSUF; SARANDÖL, ASLI; EKER, SALİH SAYGIN; KIRLI, SELÇUK; Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.; Q-9477-2019; EKJ-8427-2022; GBQ-8020-2022; FTX-6743-2022; CZU-1387-2022Objective: In this study we aimed to compare the effects of sertraline and reboxetine, which are influential on two different neurotransmitters, on social functioning.Method: 41 patients conforming to the study protocol and who met DSM-IV MDD diagnostic criteria were recruited for the study. These subjects were distributed randomly into two groups, sertraline and reboxetine. The subjects were assessed six times during the study which lasted 11 weeks. At each assessment the subjects were asked to complete "Hamilton Depression Rating Scale" (HDRS), "Montgomery-Asberg Depression Rating Scale" (MADRS) and "Social Adaptation Self-evaluation Scale (SASS).Results: In both groups, the decrease in HDRS and MADRS scores was found to be statistically significant starting from the 2nd visit, compared to the values prior to medication. The decrease in SASS scores, on the other hand, was significant starting from the 3rd visit. In comparison of reboxetine and sertraline groups, HDRS scores were found to be significantly higher in the reboxetine group in visits 2, 3, and 4. However, no significant difference was found in MADRS and SASS scores.Discussion and Conclusion: In this study two antidepressants which create a selective effect via serotonin and noradrenalin were compared and it was found that clinically an earlier response and remission was provided with reboxetine. Nevertheless, it is notable that there was no statistically significant difference on their social functioning levels.